Total Payments
$220,793
2024 Payments
$25,250
Companies
6
Transactions
35
Medicare Patients
3,618
Medicare Billing
$151,685
Payment Breakdown by Category
Research$158,298 (71.7%)
Consulting$62,495 (28.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $158,298 | 12 | 71.7% |
| Consulting Fee | $62,495 | 23 | 28.3% |
Payments by Type
Research
$158,298
12 transactions
General
$62,495
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $141,838 | 10 | $0 (2024) |
| PFIZER INC. | $55,248 | 20 | $0 (2019) |
| GUERBET LLC | $16,460 | 2 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,160 | 1 | $0 (2019) |
| Celgene Corporation | $2,000 | 1 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $87.50 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,250 | 2 | Eli Lilly and Company ($25,250) |
| 2023 | $68,575 | 2 | Eli Lilly and Company ($68,575) |
| 2022 | $46,288 | 2 | Eli Lilly and Company ($46,288) |
| 2021 | $2,388 | 3 | Celgene Corporation ($2,000) |
| 2020 | $775.00 | 2 | Eli Lilly and Company ($775.00) |
| 2019 | $13,602 | 13 | PFIZER INC. ($8,442) |
| 2018 | $15,803 | 5 | PFIZER INC. ($15,803) |
| 2017 | $48,113 | 6 | PFIZER INC. ($31,003) |
All Payment Transactions
35 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $87.50 | Research |
| Study: LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | ||||||
| 02/08/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $25,162.50 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 06/07/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,287.50 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 01/05/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $63,287.50 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 12/07/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $44,200.00 | Research |
| Study: LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | ||||||
| 06/08/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,088.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 12/07/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $87.50 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2021 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 02/04/2021 | Eli Lilly and Company | — | — | Cash or cash equivalent | $300.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 11/06/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $600.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | ||||||
| 03/18/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $175.00 | Research |
| Study: LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | ||||||
| 12/11/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $5,160.00 | General |
| 11/20/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| Category: ONCOLOGY | ||||||
| 07/01/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $1,225.00 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $1,207.50 | General |
| Category: ONCOLOGY | ||||||
| 04/04/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $612.50 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $584.50 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2019 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $1,662.50 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2018 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $1,365.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | Eli Lilly and Company | $88,450 | 2 |
| LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $44,375 | 2 |
| Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) | GUERBET LLC | $16,460 | 2 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $5,288 | 1 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $2,988 | 3 |
| PHASE 1B-2A STUDY COMBINING LY2157299 WITH STANDARD TEMOZOLOMIDE-BASED RADIO CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT GLIOMA | Eli Lilly and Company | $650.00 | 1 |
| LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | Eli Lilly and Company | $87.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 919 | 2,053 | $207,264 | $35,291 |
| 2022 | 21 | 959 | 2,849 | $288,440 | $42,900 |
| 2021 | 20 | 983 | 1,872 | $200,928 | $40,019 |
| 2020 | 19 | 757 | 785 | $152,869 | $33,476 |
Total Patients
3,618
Total Services
7,559
Medicare Billing
$151,685
Procedure Codes
92
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 70450 | Ct scan head or brain without contrast | Facility | 2023 | 245 | 259 | $38,850 | $7,471 | 19.2% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2023 | 69 | 71 | $26,128 | $5,724 | 21.9% |
| 70498 | Ct scan of blood vessels of neck with contrast | Facility | 2023 | 70 | 70 | $21,560 | $4,069 | 18.9% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 14 | 14 | $41,804 | $3,240 | 7.8% |
| 70496 | Ct scan of blood vessels of head with contrast | Facility | 2023 | 49 | 49 | $15,092 | $2,968 | 19.7% |
| 72125 | Ct scan of upper spine without contrast | Facility | 2023 | 79 | 80 | $14,107 | $2,597 | 18.4% |
| 70551 | Mri scan of brain without contrast | Facility | 2023 | 27 | 27 | $6,210 | $1,439 | 23.2% |
| 72132 | Ct scan of lower spine with contrast | Facility | 2023 | 36 | 36 | $7,740 | $1,389 | 18.0% |
| 72129 | Ct scan of middle spine with contrast | Facility | 2023 | 35 | 35 | $7,525 | $1,350 | 17.9% |
| 70491 | Ct scan of soft tissue of neck with contrast | Facility | 2023 | 23 | 24 | $5,856 | $1,178 | 20.1% |
| 70486 | Ct scan of face without contrast | Facility | 2023 | 22 | 22 | $3,344 | $644.59 | 19.3% |
| 72148 | Mri scan of lower spinal canal without contrast | Facility | 2023 | 11 | 11 | $2,882 | $604.52 | 21.0% |
| 72131 | Ct scan of lower spine without contrast | Facility | 2023 | 16 | 16 | $2,832 | $508.63 | 18.0% |
| 72110 | X-ray of lower and sacral spine, minimum of 4 views | Office | 2023 | 52 | 53 | $2,438 | $460.13 | 18.9% |
| A9585 | Injection, gadobutrol, 0.1 ml | Office | 2023 | 15 | 1,124 | $3,586 | $296.87 | 8.3% |
| 72050 | X-ray of upper spine, 4-5 views | Office | 2023 | 29 | 29 | $1,421 | $278.64 | 19.6% |
| 72050 | X-ray of upper spine, 4-5 views | Facility | 2023 | 24 | 26 | $1,274 | $216.72 | 17.0% |
| 72110 | X-ray of lower and sacral spine, minimum of 4 views | Facility | 2023 | 23 | 23 | $1,058 | $186.01 | 17.6% |
| 72083 | X-ray of entire middle and lower spine, 4-5 views | Office | 2023 | 14 | 14 | $910.00 | $161.88 | 17.8% |
| 72040 | X-ray of upper spine, 2-3 views | Facility | 2023 | 18 | 19 | $760.00 | $143.65 | 18.9% |
| 70250 | X-ray of skull, 1-3 views | Facility | 2023 | 13 | 14 | $504.00 | $96.04 | 19.1% |
| 72100 | X-ray of lower and sacral spine, 2-3 views | Facility | 2023 | 13 | 13 | $520.00 | $95.19 | 18.3% |
| 71046 | X-ray of chest, 2 views | Facility | 2023 | 11 | 12 | $468.00 | $90.20 | 19.3% |
| 74018 | X-ray of abdomen, 1 view | Facility | 2023 | 11 | 12 | $396.00 | $80.86 | 20.4% |
| 70450 | Ct scan head or brain without contrast | Facility | 2022 | 236 | 255 | $38,250 | $7,478 | 19.6% |
About Dr. Jonathan Burdette, MD
Dr. Jonathan Burdette, MD is a Neuroradiology healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528043940.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Burdette, MD has received a total of $220,793 in payments from pharmaceutical and medical device companies, with $25,250 received in 2024. These payments were reported across 35 transactions from 6 companies. The most common payment nature is "" ($158,298).
As a Medicare-enrolled provider, Burdette has provided services to 3,618 Medicare beneficiaries, totaling 7,559 services with total Medicare billing of $151,685. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Ad
Practice Information
- Specialty Neuroradiology
- Other Specialties Vascular & Interventional Radiology
- Location Winston Salem, NC
- Active Since 12/08/2005
- Last Updated 10/08/2010
- Taxonomy Code 2085N0700X
- Entity Type Individual
- NPI Number 1528043940
Products in Payments
- LORBRENA (Drug) $24,245
- KEYTRUDA (Biological) $87.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neuroradiology Doctors in Winston Salem
Dr. Morry Brown, M.d, M.D
Neuroradiology — Payments: $1,668
Neuroradiology $1,668
Tyler Combs, Do, DO
Neuroradiology — Payments: $450.73
Neuroradiology $450.73
Marc Benayoun, M.d., Ph.d, M.D., PH.D
Neuroradiology — Payments: $138.10
Neuroradiology $138.10
William Patton, Md, MD
Neuroradiology — Payments: $78.21
Neuroradiology $78.21
Allen Elster, Md, MD
Neuroradiology — Payments: $53.23
Neuroradiology $53.23
Michael Baker, Md, MD
Neuroradiology — Payments: $13.75
Neuroradiology $13.75